Stock Events

Stock Events

Molecular Pharmacology (USA) 

$0.020200
2
+$0.00+0%Monday 20:00

Statistics

Day High
0.001
Day Low
0.0002
52W High
0.485
52W Low
0.0002
Volume
125,000
Avg. Volume
65
Mkt Cap
20.19M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Sep 30Expected
Q4 2012
Q1 2013
Q2 2013
Q3 2013
Q4 2013
Q1 2014
Q2 2014
-0
-0
-0
0
Expected EPS
0
Actual EPS
-0.0003

Financials

-Profit Margin
Unprofitable
2015
2021
2023
2024
2025
2026
0Revenue
-1,000Net Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap158.45B
Pfizer is a major player in the pharmaceutical industry, directly competing in the development and marketing of medications similar to those of MLPH.
Merck
MRK
Mkt Cap356.01B
Merck operates in various therapeutic areas that overlap with MLPH's interests, making them direct competitors in pharmaceuticals.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson, through its pharmaceutical division, competes in the same sectors as MLPH, particularly in drug development.
GSK
GSK
Mkt Cap94.23B
GlaxoSmithKline competes with MLPH in the research and development of new drugs, sharing several therapeutic areas.
Novartis
NVS
Mkt Cap268B
Novartis is involved in extensive research and development in the pharmaceutical field, competing with MLPH in multiple drug markets.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie operates in similar therapeutic areas as MLPH, particularly in specialized drugs, making them a key competitor.
AMGEN
AMGN
Mkt Cap217.9B
Amgen focuses on innovative therapeutics, directly competing with MLPH in the biopharmaceutical sector.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol-Myers Squibb's broad range of pharmaceutical products pits them against MLPH in several key areas of drug development.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly and Company's strong focus on pharmaceutical innovation and similar market segments makes them a direct competitor to MLPH.
Sanofi
SNY
Mkt Cap95.65B
Sanofi operates globally in the pharmaceutical industry, competing with MLPH in areas like diabetes and oncology treatments.

About

As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is dedicated to the creation and market introduction of solutions for pain and inflammation, with a primary focus on the Australian and United States markets. Through its subsidiary, Molecular Pharmacology Pty. Ltd., it is advancing an analgesic and anti-inflammatory molecule called Tripeptofen, designed to alleviate common daily pain. These products are offered in diverse dosage forms, formulations, and packaging options to suit various needs. MLPH's marketing strategy involves leveraging pharmaceutical distributors and forging collaborative partnerships with companies in the United States and Europe. Additionally, the company maintains an agreement with Dermatology Development Corporation to jointly develop and market a suite of therapeutic, cosmetic, and cosmeceutical items derived from the ThermaLIFE product line and its core active component. Headquartered in Perth, Australia, Molecular Pharmacology (USA) Limited operates as a subsidiary of PharmaNet Group Limited.
Show More
CEO
Jeffrey David Edwards
Employees
1
Country
United States
ISIN
US60852T1097

Listings

OTC Link
US
ENAI
OTCM
US
MLPH

0 Comments

Share your thoughts

FAQs

What is Molecular Pharmacology (USA) stock price today?▼
The current price of MLPH is $0.02 USD — it has increased by +0% in the past 24 hours. Watch Molecular Pharmacology (USA) stock price performance more closely on the chart.
What is Molecular Pharmacology (USA) stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCM exchange Molecular Pharmacology (USA) stocks are traded under the ticker MLPH.
What is Molecular Pharmacology (USA) market cap?▼
Today Molecular Pharmacology (USA) has the market capitalization of 20.19M
What were Molecular Pharmacology (USA) earnings last quarter?▼
MLPH earnings for the last quarter are -0 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Molecular Pharmacology (USA) revenue for the last year?▼
Molecular Pharmacology (USA) revenue for the last year amounts to 0 USD.
What is Molecular Pharmacology (USA) net income for the last year?▼
MLPH net income for the last year is -1,000 USD.
How many employees does Molecular Pharmacology (USA) have?▼
As of November 1, 2026, the company has 1 employees.
In which sector is Molecular Pharmacology (USA) located?▼
Molecular Pharmacology (USA) operates in the Finance & Payments sector.
When did Molecular Pharmacology (USA) complete a stock split?▼
The last stock split for Molecular Pharmacology (USA) was on June 18, 2026 with a ratio of 1:50.
Where is Molecular Pharmacology (USA) headquartered?▼
Molecular Pharmacology (USA) is headquartered in Shanghai, United States.